The Effects of Live High-train Low on EPO, VEGF, and Hematological Variables in Elite Rowers
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 主要终点
- Erythropoietin (EPO) mlU/ml
研究概览
简要总结
The response to hypoxia is very individual and depending on many aspects, such as the type of training, duration, intensity, or hypoxic stimulus, hypoxia affects the athlete in various ways. This multi-stage study investigated hematological and physiological responses to normobaric Live High-Train Low (LHTL) exposure in elite male rowers from the Polish national rowing team. Stage I evaluated responses during an 18-day LHTL intervention, whereas Stage II evaluated responses during a 14-day LHTL intervention and extended the assessment to 42 days after return to normoxia. The study focused particularly on hematological variables, erythropoietin (EPO), vascular endothelial growth factor (VEGF), and other physiological and biochemical responses associated with hypoxic exposure.
详细描述
I stage. The Polish national rowing team athletes, 13 males, were randomly divided into two groups:
- The hypoxic group (H) included 8 rowers participating in sports training and the LHTL intervention, with progressive normobaric hypoxic exposure corresponding to simulated altitudes of 2000, 2500, and 3000 m.
- The control group (C) consisted of 5 rowers participating only in sports training and living in normoxic rooms at the same sports camp. Rowers were observed during the preparatory period. The hypoxic group lived and slept in hypoxic rooms for at least 8-14 hours per day. During the camp, all rowers followed the same training schedule and diet. All participants' saturation and heart rate were measured daily, morning and evening, throughout the camp period. Venous blood samples were taken four times, at the beginning of the camp (Baseline), after 6 days, after 12 days, and after 18 days of the camp. Body composition parameters such as body mass index, body fat, and free fat mass were estimated using the bioelectrical impedance method of a Tanita BC 418 analyzer (Japan). Data analysis was performed using Statistica. The response to hypoxia is very individual. Depending on many factors, such as training type, duration, intensity, or hypoxic stimulus, hypoxia affects athletes in various ways. The results of this study have shown that the blood parameters did not increase significantly in the hypoxic group compared to the control group. However, reticulocytes, immature red blood cells, have shown significant differences after 18-d LHTL between groups. Further research should be carried out to investigate an optimal hypoxic dose and time, which will raise EPO, VEGF, and morphology variables.
II stage. Fourteen elite male rowers from the Polish national rowing team participated in the second stage and were randomly allocated to the LHTL group (n = 8) or the normoxic control group (n = 6). Both groups followed the same standardized training program. The LHTL intervention lasted 14 consecutive days and involved progressive normobaric hypoxic exposure corresponding to 2000-3000 m for approximately 14-16 h/day, while all training sessions were performed under normoxic conditions. Blood samples were collected at baseline, after 7 and 14 days of the intervention, and 8, 14, and 42 days after completion. Hematological variables, EPO, VEGF, iron-related indices, CK activity, and lipid-profile variables were assessed, while SpO₂ and resting HR were monitored throughout the intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
盲法说明
Participants were randomly assigned to one of two parallel groups: a hypoxic Live High-Train Low (LHTL) group, which underwent the same sports training while living in normobaric hypoxic conditions, and a control (CON) group, which completed the same training while living in normoxic conditions.
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male national-team rowers aged ≥18 years.
- •Regular participation in rowing training.
- •Participation in the training camp.
排除标准
- •Exposure to hypoxic conditions or altitude above 1500 m within 1 month before the study.
- •Medical contraindications or adverse symptoms associated with hypoxic exposure.
- •Injury or health condition preventing participation in the training program.
研究组 & 干预措施
LHTL
Participants assigned to the LHTL group underwent their regular sports training while living in normobaric hypoxic rooms.
干预措施: Normobaric hypoxia (LHTL) (Other)
Control group
Participants assigned to the control group completed the same sports training as the LHTL group while living in normoxic conditions at the same training camp.
结局指标
主要结局
Erythropoietin (EPO) mlU/ml
时间窗: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
immunoenzymatic assay methods using diagnostic kits
Vascular endothelial growth factor (VEGF) mlU/ml
时间窗: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
immunoenzymatic assay methods using diagnostic kits
次要结局
- Creatine kinase (CK) ng/ml(Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.)
- Hs C-Reactive Protein (hsCRP) mg/L(Stage 1: at baseline and on days 6, 12, and 18 of the intervention.)
- Hemoglobin (Hb)g/dL(Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.)
- Hematocrit (Htc)%(Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.)
- Red blood cells (RBC)mln/mm3(Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.)
- White blood cells (WBC)10 3/µL(Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.)
- Reticulocytes (Ret)‰(Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.)
- Peripheral oxygen saturation (SpO₂) (%)(Stage 1: daily from Day 1 through Day 18 of the intervention, in the morning after waking and in the evening before bedtime; Stage 2: daily from Day 1 through Day 14 of the intervention, in the morning after waking and in the evening before bedtime.)
- Heart rate (HR) (beats/min)(Stage 1: daily from Day 1 through Day 18 of the intervention; Stage 2: daily from Day 1 through Day 14 of the intervention.)
